Literature DB >> 10211522

Human leukocyte antigens as genetic markers in colorectal carcinoma.

M A Chatzipetrou1, K E Tarassi, M M Konstadoulakis, H E Pappas, K D Zafirellis, T E Athanassiades, S A Papadopoulos, D G Panousopoulos, B C Golematis, C A Papasteriades.   

Abstract

PURPOSE: Similar to findings obtained for most carcinomas, the pathogenesis of colorectal cancer is considered to be multifactorial. There is strong evidence for an inherited, genetic predisposition to disease in patients with familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer. There is still debate, however, about the contribution of genetic factors to the pathogenesis of sporadic colorectal cancer. The present study was undertaken to search for human leukocyte antigen associations in a group of patients with colorectal cancer and to correlate the findings with both the histology of the disease and family history. SUBJECTS AND METHODS: The allele frequencies of serologically defined human leukocyte antigen class I and II antigens were studied in 101 patients with a recent, histologically confirmed diagnosis of colorectal cancer. All individuals in this study were unrelated to each other. After surgical treatment, all patients were grouped according to the stage (Dukes Stages A, B, C, and D), differentiation (Grades 1, 2, and 3), and the site of the tumor. Patients were also classified with regard to family history for colorectal cancer. The results obtained for human leukocyte antigen frequencies were compared with those of 105 healthy control subjects (control group).
RESULTS: An increased frequency of human leukocyte antigen-B18 (27.72 vs. 14.28 percent; P < 0.025; odds ratio = 2.3) and of human leukocyte antigen-DQ5 (43.56 vs. 22.5 percent; P < 0.01; odds ratio = 2.65) was observed for patients with colorectal cancer vs. control subjects, respectively. In addition, human leukocyte antigen-B18 was present with increased frequency (30.76 percent; P < 0.05; odds ratio = 2.66; and 26.67 percent; P < 0.05; odds ratio = 2.18) among patients with rectal and colon carcinoma, respectively. A higher frequency of human leukocyte antigen-DQ5 (45.33 percent; P < 0.01; odds ratio = 2.84) was observed among patients with colon carcinoma. Remarkably, human leukocyte antigen-DQ5 (50 vs. 22.5 percent; P < 0.05; odds ratio = 3.43) and human leukocyte antigen-A1 (41.66 vs. 12.38 percent; P < 0.01; odds ratio = 5.05) were found to be strongly associated with a family history of colorectal cancer.
CONCLUSION: The observation of specific human leukocyte antigen associations with particular subsets of colorectal cancer strongly suggests that genetic susceptibility for the development of colorectal cancer exists. Although the multifactorial pathogenesis of colorectal cancer must be considered, human leukocyte antigens may have useful predictive and diagnostic value.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10211522     DOI: 10.1007/bf02235184

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  4 in total

Review 1.  The bodies fight against cancer: is human leucocyte antigen (HLA) class 1 the key?

Authors:  Arfon G M T Powell; Paul G Horgan; Joanne Edwards
Journal:  J Cancer Res Clin Oncol       Date:  2012-03-18       Impact factor: 4.553

2.  Brain glioma and human leukocyte antigens (HLA)--is there an association.

Authors:  H K Machulla; F Steinborn; A Schaaf; V Heidecke; N G Rainov
Journal:  J Neurooncol       Date:  2001-05       Impact factor: 4.130

3.  Primary CNS lymphoma and HLA class I and II alleles in a German cohort of immunocompetent patients.

Authors:  Delia Kurzwelly; Claudia A Müller; Agnieszka Korfel; Eckhard Thiel; Michael Linnebank; Michael Weller; Ulrich Herrlinger
Journal:  J Neurooncol       Date:  2008-06-28       Impact factor: 4.130

4.  HLA-DRB1 allele polymorphisms in genetic susceptibility to esophageal carcinoma.

Authors:  Jun Lin; Chang-Sheng Deng; Jie Sun; Xian-Gong Zheng; Xing Huang; Yan Zhou; Ping Xiong; Ya-Ping Wang
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.